- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04334109
Comparative Effectiveness of Family DSMES and Standard DSMES Among Diverse Populations
February 15, 2024 updated by: University of Arkansas
The investigators will conduct a fully-powered, comparative effectiveness randomized controlled trial that includes up to 600 patients with type 2 diabetes (T2D) and 600 of their family members.
Patients with T2D will be randomly assigned to either the Family-DSMES arm or the Standard-DSMES arm, with 300 patients in each arm.
In the Family-DSMES arm, one of each patient's family members will take part in the educational sessions (family members defined below).
Baseline and follow-up data (immediate post-intervention, 6 months post-intervention, and 12 months post-intervention) will be collected from patients and family members in both study arms.
In the Standard-DSMES arm, data will be collected from family members, but they will not participate in educational sessions.
In both arms, the investigators will obtain a medical records release to abstract outcomes at 18 months post-intervention.
Study Overview
Status
Active, not recruiting
Conditions
Study Type
Interventional
Enrollment (Estimated)
1200
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Brett Rowland, MA
- Phone Number: 479-713-8000
- Email: mbrowland@uams.edu
Study Locations
-
-
Arkansas
-
Fayetteville, Arkansas, United States, 72703
- University of Arkansas for Medical Sciences Northwest
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- adults ≥18 years of age
- have T2D (HbA1c ≥ 7.0)
- speak English
- a family member willing to take part in the study
Exclusion Criteria:
- have received formal DSME in the past three years
- have a condition that makes it unlikely for them to be able to follow the protocol
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Family-DSME
Approach
|
Family Diabetes Self-Management Education and Support demonstrates the effectiveness of family-centered models of DSME that explicitly address diabetes self-management within a family context by educating both patients and family members and focusing on family motivational interviewing, family goal setting, understanding supportive and nonsupportive behaviors, and family behavioral changes.
|
Active Comparator: Standard-DSME
Approach
|
Diabetes Self-Management Education and Support demonstrates the effectiveness of individual model DSMES that explicitly address diabetes self-management within an individual context by educating individual patients on individual motivational interviewing, individual goal setting, and individual behavioral changes.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in mean HbA1c (NGSP%) from baseline to immediate post-intervention, 6 months post-intervention, 12 months post-intervention, and 18 months post-intervention
Time Frame: Baseline, immediate post-intervention, 6 months post-intervention, 12 months post-intervention, and 18 months post-intervention
|
A Siemens analyzer will be utilized to calculate HbA1c (%) for each participant at every time point (except for 18 months post-intervention, which will be collected through medical record abstractions).
Changes in the primary outcome measure will be assessed from baseline to each follow-up time point.
The primary analytic approach will use general linear models, including mixed effects linear regression models for continuous repeated measures, to model the mean outcome difference and covariance structures between the treatment arms.
Analyses will be adjusted for baseline differences in demographic, socioeconomic, and clinical variables, all within repeated mixed linear regression models.
Clustering effects within the intervention delivery groups (i.e., within the DSMES classes) will be accounted for in the model as a random effect.
We will adjust for potential clinic variations as a dummy coded variable in our model.
|
Baseline, immediate post-intervention, 6 months post-intervention, 12 months post-intervention, and 18 months post-intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in mean BMI from baseline to immediate post-intervention, 6 months post-intervention, 12 months post-intervention, and 18 months post-intervention
Time Frame: Baseline, immediate post-intervention, 6 months post-intervention, 12 months post-intervention, and 18 months post-intervention
|
BMI will be collected by measuring participant height (without shoes) using a stadiometer, and measuring participant weight (without shoes) using a calibrated digital scale.
Weight and height will be used to compute a continuous measure of BMI.
BMI at 18 months post-intervention will be abstracted from participant medical records.
The analytic approach for secondary outcomes will be similar to those used for the primary outcome.
|
Baseline, immediate post-intervention, 6 months post-intervention, 12 months post-intervention, and 18 months post-intervention
|
Change in mean waist circumference from baseline to immediate post-intervention, 6 months post-intervention, 12 months post-intervention, and 18 months post-intervention medical record abstraction
Time Frame: Baseline, immediate post-intervention, 6 months post-intervention, 12 months post-intervention, and 18 months post-intervention
|
Waist circumference will be collected by measuring participant's waist using a flexible tape measure.
Waist circumference at 18 months post-intervention will be abstracted from participant medical records.The analytic approach for secondary outcomes will be similar to those used for the primary outcome.
|
Baseline, immediate post-intervention, 6 months post-intervention, 12 months post-intervention, and 18 months post-intervention
|
Change in mean blood pressure (systolic & diastolic, mmHg) from baseline to immediate post-intervention, 6 months post-intervention, 12 months post-intervention, and 18 months post-intervention
Time Frame: Baseline, immediate post-intervention, 6 months post-intervention, 12 months post-intervention, and 18 months post-intervention
|
Blood pressure will be measured with a sphygmomanometer and stethoscope or digital blood pressure device with the participant seated and arm elevated.
Blood pressure at 18 months post-intervention will be abstracted from participant medical records.The analytic approach for secondary outcomes will be similar to those used for the primary outcome.
|
Baseline, immediate post-intervention, 6 months post-intervention, 12 months post-intervention, and 18 months post-intervention
|
Change in mean total cholesterol (mg/dL) from baseline to immediate post-intervention, 6 months post-intervention, 12 months post-intervention, and 18 months post-intervention
Time Frame: Baseline, immediate post-intervention, 6 months post-intervention, 12 months post-intervention, and 18 months post-intervention medical records abstraction
|
Through finger prick blood collection, point of care tests will be used used to test lipids using a commercial lipid panel kit and Cholestech LDX analyzer.
Total cholesterol at 18 months post-intervention will be abstracted from participant medical records.
The analytic approach for secondary outcomes will be similar to those used for the primary outcome.
|
Baseline, immediate post-intervention, 6 months post-intervention, 12 months post-intervention, and 18 months post-intervention medical records abstraction
|
Change in mean high-density lipoproteins (HDL) from baseline to immediate post-intervention, 6 months post-intervention, 12 months post-intervention, and 18 months post-intervention
Time Frame: Baseline, immediate post-intervention, 6 months post-intervention, 12 months post-intervention, and 18 months post-intervention
|
Through finger prick blood collection, point of care tests will be used used to test HDL using a commercial lipid panel kit and Cholestech LDX analyzer.
HDL at 18 months post-intervention will be abstracted from participant medical records.
The analytic approach for secondary outcomes will be similar to those used for the primary outcome.
|
Baseline, immediate post-intervention, 6 months post-intervention, 12 months post-intervention, and 18 months post-intervention
|
Change in mean low-density lipoproteins (LDL) from baseline to immediate post-intervention, 6 months post-intervention, 12 months post-intervention, and 18 months post-intervention
Time Frame: Baseline, immediate post-intervention, 6 months post-intervention, 12 months post-intervention, and 18 months post-intervention
|
Through finger prick blood collection, point of care tests will be used used to test HDL using a commercial lipid panel kit and Cholestech LDX analyzer.
LDL Blood pressure at 18 months post-intervention will be abstracted from participant medical records.
The analytic approach for secondary outcomes will be similar to those used for the primary outcome.
|
Baseline, immediate post-intervention, 6 months post-intervention, 12 months post-intervention, and 18 months post-intervention
|
Change in mean triglycerides from baseline to immediate post-intervention, 6 months post-intervention, 12 months post-intervention, and 18 months post-intervention
Time Frame: Baseline, immediate post-intervention, 6 months post-intervention, 12 months post-intervention, and 18 months post-intervention
|
Through finger prick blood collection, point of care tests will be used used to test triglycerides using a commercial lipid panel kit and Cholestech LDX analyzer.
Triglycerides at 18 months post-intervention will be abstracted from participant medical records.
The analytic approach for secondary outcomes will be similar to those used for the primary outcome.
|
Baseline, immediate post-intervention, 6 months post-intervention, 12 months post-intervention, and 18 months post-intervention
|
Change in mean blood glucose from baseline to immediate post-intervention, 6 months post-intervention, 12 months post-intervention, and 18 months post-intervention
Time Frame: Baseline, immediate post-intervention, 6 months post-intervention, 12 months post-intervention, and 18 months post-intervention
|
Through finger prick blood collection, point of care tests will be used used to test random blood glucose (not fasting).
Blood glucose at 18 months post-intervention will be abstracted from participant medical records.
The analytic approach for secondary outcomes will be similar to those used for the primary outcome.
|
Baseline, immediate post-intervention, 6 months post-intervention, 12 months post-intervention, and 18 months post-intervention
|
Change in diabetes self-management behaviors from baseline to immediate post-intervention, 6 months post-intervention, and 12 months post-intervention
Time Frame: Baseline, immediate post-intervention, 6 months post-intervention, and 12 months post-intervention
|
The Summary of Diabetes Self-Care Activities (SDSCA) will be used to measure engagement in self-management activities.
The SDSCA consists of 12 items to assess the self-reported frequency of performing diabetes self-care tasks, including testing blood sugar, following healthful eating plans, and exercising regularly.
The SDSCA will be administered to participants at baseline, immediate post-intervention, 6 months post-intervention, and 12 months post-intervention.
The analytic approach for secondary outcomes will be similar to those used for the primary outcome.
|
Baseline, immediate post-intervention, 6 months post-intervention, and 12 months post-intervention
|
Change in diabetes self-efficacy from baseline to immediate post-intervention, 6 months post-intervention, and 12 months post-intervention
Time Frame: Baseline, immediate post-intervention, 6 months post-intervention, and 12 months post-intervention
|
The Diabetes Management Self-Efficacy Scale (DMSES) will be used to measure patient's confidence in managing their diabetes.
The DMSES consists of 20 items to assess self-reported confidence in managing aspects of their diabetes.
The DMSES will be administered to participants at baseline, immediate post-intervention, 6 months post-intervention, and 12 months post-intervention.
The analytic approach for secondary outcomes will be similar to those used for the primary outcome.
|
Baseline, immediate post-intervention, 6 months post-intervention, and 12 months post-intervention
|
Change in medication adherence from baseline to immediate post-intervention, 6 months post-intervention, and 12 months post-intervention
Time Frame: Baseline, immediate post-intervention, 6 months post-intervention, and 12 months post-intervention
|
The Adherence to Refills and Medications Scale for Diabetes Medicines (ARMS-D) will be used to measure patient's adherence to their medications (if prescribed).
The ARMS-D consists of 11 items to assess self-reported adherence to diabetes medications.
The ARMS-D will be administered to participants at baseline, immediate post-intervention, 6 months post-intervention, and 12 months post-intervention.
The analytic approach for secondary outcomes will be similar to those used for the primary outcome.
|
Baseline, immediate post-intervention, 6 months post-intervention, and 12 months post-intervention
|
Change in diabetes-related distress from baseline to immediate post-intervention, 6 months post-intervention, and 12 months post-intervention
Time Frame: Baseline, immediate post-intervention, 6 months post-intervention, and 12 months post-intervention
|
The Problem Areas in Diabetes Scale (PAID)-5 will be used to measure diabetes distress.
The PAID-5 consists of 5 items to assess self-reported diabetes-related emotional distress, including feeling scared or depressed.
The PAID-5 will be administered to participants at baseline, immediate post-intervention, 6 months post-intervention, and 12 months post-intervention.
The analytic approach for secondary outcomes will be similar to those used for the primary outcome.
|
Baseline, immediate post-intervention, 6 months post-intervention, and 12 months post-intervention
|
Change in diabetes-related quality of life from baseline to immediate post-intervention, 6 months post-intervention, and 12 months post-intervention
Time Frame: Baseline, immediate post-intervention, 6 months post-intervention, and 12 months post-intervention
|
The DAWN2 Impact of Diabetes Profile (DIDP) will be used to measure the perceived impact of diabetes on patients' quality of life.
The DIDP consists of 6 items to assess self-reported impacts on quality of life, including physical health, financial situation, and relationships with others.
The DIDP will be administered to participants at baseline, immediate post-intervention, 6 months post-intervention, and 12 months post-intervention.
The analytic approach for secondary outcomes will be similar to those used for the primary outcome.
|
Baseline, immediate post-intervention, 6 months post-intervention, and 12 months post-intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Pearl McElfish, PhD, UAMS
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 4, 2021
Primary Completion (Estimated)
July 2, 2024
Study Completion (Estimated)
August 1, 2025
Study Registration Dates
First Submitted
March 26, 2020
First Submitted That Met QC Criteria
April 1, 2020
First Posted (Actual)
April 6, 2020
Study Record Updates
Last Update Posted (Actual)
February 16, 2024
Last Update Submitted That Met QC Criteria
February 15, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 260059
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
AstraZenecaNot yet recruiting
Clinical Trials on Family Diabetes Self-Management Education and Support
-
University of ArkansasNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Recruiting
-
University of ArkansasNational Institute on Minority Health and Health Disparities (NIMHD)RecruitingType 2 DiabetesUnited States
-
University of MichiganRecruiting
-
University of MichiganNational Institutes of Health (NIH); National Institute on Aging (NIA); Blue...Completed
-
University of MichiganNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
State University of New York - Upstate Medical...National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...Completed
-
State University of New York - Upstate Medical...National Institutes of Health (NIH); Syracuse UniversityCompleted
-
Omada Health, Inc.Palo Alto Medical Foundation; Sutter HealthTerminatedType 2 DiabetesUnited States
-
NYU Langone HealthAgency for Healthcare Research and Quality (AHRQ)Not yet recruitingType 2 DiabetesUnited States
-
Region Jönköping CountyLinkoeping University; Region Östergötland; Uppsala County Council, Sweden; Medical... and other collaboratorsRecruitingType 2 DiabetesSweden